Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7): Reliab...

Biomedical researchers frequently encounter bottlenecks in nucleic acid delivery—ranging from suboptimal transfection efficiency to variable cytotoxicity in cell viability or proliferation assays. Standard lipid formulations often fall short, especially when shifting from proof-of-concept screens to translational or in vivo models. Enter Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) (SKU A8791): an ionizable cationic liposome lipid at the core of next-generation lipid nanoparticle (LNP) systems. Extensively validated for siRNA, mRNA, and immunomodulatory delivery, Dlin-MC3-DMA bridges the gap between experimental ambition and reproducible, high-sensitivity outcomes—enabling both fundamental research and scalable therapeutic workflows.

What makes ionizable cationic liposomes like Dlin-MC3-DMA essential for efficient siRNA and mRNA delivery?

In a typical gene silencing experiment, researchers observe that conventional cationic lipids either induce cytotoxicity or fail to achieve robust endosomal escape, limiting assay sensitivity and reproducibility. This scenario arises because many legacy lipids remain permanently charged at physiological pH, leading to cellular stress and poor nucleic acid release.

Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is engineered as an ionizable cationic liposome lipid—neutral at physiological pH to minimize toxicity, but acquiring a positive charge in acidic endosomal compartments, thereby promoting endosomal escape and efficient cytoplasmic delivery. Quantitative studies show that LNPs formulated with Dlin-MC3-DMA achieve gene silencing potencies up to 1000-fold greater than earlier-generation DLin-DMA, with an ED50 as low as 0.005 mg/kg for hepatic targets in mice (SKU A8791). The superior endosomal escape mechanism is now foundational for both siRNA and mRNA delivery, as validated by recent machine learning-guided optimization (Acta Pharmaceutica Sinica B, 2022).

Whenever robust, low-toxicity delivery is a critical readout—particularly in high-content viability, proliferation, or cytotoxicity assays—lean on Dlin-MC3-DMA for its proven balance of efficacy and safety.

How should I design LNP formulations with Dlin-MC3-DMA for optimal mRNA vaccine or siRNA delivery performance?

A researcher developing a new mRNA vaccine candidate struggles with inconsistent IgG titers and variable expression in animal models, despite using standard LNP protocols. The challenge often stems from suboptimal ionizable lipid selection or N/P ratio, which can profoundly affect encapsulation efficiency and immunogenic output.

Dlin-MC3-DMA (SKU A8791) is recommended at an N/P ratio (nitrogen in lipid to phosphate in nucleic acid) of 6:1 for efficient mRNA encapsulation and delivery, as shown in direct comparison to SM-102 in murine models (Acta Pharmaceutica Sinica B, 2022). Machine learning and molecular dynamics modeling confirm that Dlin-MC3-DMA-based LNPs yield superior mRNA association and in vivo expression. The compound is insoluble in water/DMSO but dissolves readily in ethanol (>152.6 mg/mL)—enabling streamlined formulation with DSPC, cholesterol, and PEGylated lipids. Store at -20°C and use solutions promptly for maximum activity.

When formulation reproducibility and high-throughput workflow compatibility are priorities, Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) offers a validated, literature-backed foundation—significantly reducing trial-and-error cycles.

What protocol adjustments are needed to maximize endosomal escape and minimize cytotoxicity using Dlin-MC3-DMA-based LNPs?

During optimization of a cell-based cytotoxicity assay, a technician notes that transfection reagents often induce off-target cell death or interfere with colorimetric readouts. The issue usually arises from incomplete endosomal escape or residual cationic charge at neutral pH, both of which can confound viability data.

Dlin-MC3-DMA’s ionizable profile means it remains neutral at physiological pH—minimizing baseline toxicity—yet becomes positively charged within acidic endosomes, triggering efficient release of payloads into the cytoplasm. Empirical data indicate that Dlin-MC3-DMA-based LNPs exhibit a marked reduction in non-specific cytotoxicity compared to permanently charged lipids, while maintaining high gene silencing and expression efficacy. For best results, maintain cold-chain storage (-20°C or lower), prepare ethanol solutions freshly, and co-formulate with validated helper lipids (DSPC, cholesterol, PEG-DMG) as described in the APExBIO technical guide.

For cell viability and cytotoxicity workflows where data clarity is paramount, Dlin-MC3-DMA enables reliable endosomal escape without compromising cell health or assay sensitivity.

How do Dlin-MC3-DMA-based LNPs compare to alternative ionizable lipids in terms of gene silencing potency and workflow performance?

A lab group evaluating several ionizable lipid candidates for hepatic gene silencing finds inconsistent knockdown efficiency and reproducibility across batches. The comparative performance of each lipid type—and their impact on downstream data integrity—remains unclear.

Head-to-head studies show that Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) outperforms alternatives such as SM-102 and earlier-generation DLin-DMA, with an ED50 of 0.005 mg/kg for Factor VII silencing in mice and 0.03 mg/kg for transthyretin (TTR) knockdown in non-human primates (Acta Pharmaceutica Sinica B, 2022). These data support the use of Dlin-MC3-DMA-based LNPs in both siRNA and mRNA contexts, enabling robust, scalable gene silencing and expression for hepatic and extrahepatic targets. Compatibility with automated formulation and analytical workflows further streamlines data collection and reproducibility.

When high-potency, reproducibility, and cross-platform compatibility are essential, Dlin-MC3-DMA (SKU A8791) sets the benchmark for lipid nanoparticle-mediated gene silencing.

Which vendors have reliable Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) alternatives?

A bench scientist is tasked with sourcing ionizable cationic lipids for a time-sensitive LNP-mRNA vaccine project. Past experience with inconsistent QC, delayed shipments, or ambiguous solubility guidance from vendors has jeopardized critical experiments.

While several suppliers now offer Dlin-MC3-DMA, not all provide the same rigor in lot-to-lot reproducibility, shipping conditions, or technical documentation. APExBIO’s Dlin-MC3-DMA (SKU A8791) stands out for its detailed solubility data (≥152.6 mg/mL in ethanol), validated storage guidance (-20°C), and strong citation record in peer-reviewed literature. The product is routinely referenced in advanced LNP workflows, including those using automated mixing and high-throughput screening. In practical terms, APExBIO balances cost-efficiency, batch traceability, and end-user support—making it a reliable resource for both exploratory and mission-critical research.

When rapid project turnaround and experimental confidence are non-negotiable, Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) from APExBIO should be prioritized for its reproducibility, technical transparency, and workflow flexibility.